SCHEMBL3209898

SCHEMBL3209898

O=C(NCCO)c1cccc(-c2ccnc3cc(Cc4cccc(C(F)(F)F)c4)nn23)c1

nearest known ligand 0.55

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 13/20 0.55
BRAF P15056 7/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3215890 0.90 GPR52 (0.49) GPR52BRAF
SCHEMBL1851648 0.86 BRAF (0.50) BRAF
SCHEMBL1855671 0.82 BRAF (0.51) BRAF
SCHEMBL3208707 0.77 GPR52 (0.57) GPR52
SCHEMBL3220894 0.75 GPR52 (0.75) GPR52
SCHEMBL1854057 0.75 GPR52 (0.75) GPR52
SCHEMBL1849309 0.75 GPR52 (0.75) GPR52
SCHEMBL1851123 0.73 GPR52 (0.75) GPR52
SCHEMBL3204388 0.73 GPR52 (0.61) GPR52
SCHEMBL24349509 0.73 GPR52 (0.88) GPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885BRAF 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.